Medpace (MEDP) Stock Price, News & Analysis

+30.89 (+8.21%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
808,112 shs
Average Volume
249,150 shs
Market Capitalization
$12.61 billion
P/E Ratio
Dividend Yield
Price Target

Medpace MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
3.9% Downside
$395.60 Price Target
Short Interest
3.82% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.64mentions of Medpace in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$76.65 M Sold Last Quarter
Proj. Earnings Growth
From $10.53 to $12.73 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.59 out of 5 stars

Medical Sector

93rd out of 910 stocks

Commercial Physical Research Industry

4th out of 12 stocks

MEDP stock logo

About Medpace Stock (NASDAQ:MEDP)

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

MEDP Stock Price History

MEDP Stock News Headlines

The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
Medpace: Q1 Earnings Snapshot
Medpace Q1 2024 Earnings Preview
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
Medpace Holdings Inc hosts conference call for investors
Medpace (MEDP) to Release Quarterly Earnings on Monday
Should You Invest in Medpace (MEDP)?
Insiders Are Selling These 5 Stocks in 2024
MEDP Apr 2024 580.000 call
See More Headlines
Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Commercial physical research
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
$282.81 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.89 billion
Cash Flow
$10.19 per share
Book Value
$18.22 per share


Free Float
Market Cap
$11.66 billion
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

MEDP Stock Analysis - Frequently Asked Questions

Should I buy or sell Medpace stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MEDP shares.
View MEDP analyst ratings
or view top-rated stocks.

What is Medpace's stock price target for 2024?

5 equities research analysts have issued 1 year price objectives for Medpace's stock. Their MEDP share price targets range from $273.00 to $452.00. On average, they expect the company's share price to reach $395.60 in the next year. This suggests that the stock has a possible downside of 3.9%.
View analysts price targets for MEDP
or view top-rated stocks among Wall Street analysts.

How have MEDP shares performed in 2024?

Medpace's stock was trading at $306.53 at the beginning of the year. Since then, MEDP stock has increased by 34.3% and is now trading at $411.58.
View the best growth stocks for 2024 here

When is Medpace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, July 22nd 2024.
View our MEDP earnings forecast

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) issued its earnings results on Monday, April, 22nd. The company reported $3.20 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.75. The firm earned $511 million during the quarter, compared to analyst estimates of $512.39 million. Medpace had a trailing twelve-month return on equity of 63.98% and a net margin of 15.00%. Medpace's revenue for the quarter was up 17.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.27 EPS.

What guidance has Medpace issued on next quarter's earnings?

Medpace updated its FY 2024 earnings guidance on Monday, April, 22nd. The company provided earnings per share guidance of 10.790-11.470 for the period, compared to the consensus earnings per share estimate of 10.610. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace Chief Executive Officer August Troendle on August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

Medpace (MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are Medpace's major shareholders?

Medpace's stock is owned by a number of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (3.15%), Los Angeles Capital Management LLC (0.85%), Congress Asset Management Co. MA (0.50%), Raymond James & Associates (0.16%), Westwind Capital (0.14%) and Annex Advisory Services LLC (0.13%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends

How do I buy shares of Medpace?

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MEDP) was last updated on 4/23/2024 by Staff

From Our Partners